Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 157

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 2
Chunk 157
---
 the FDA authorized the importation of Kodatef from Australia, to cover any future disruption
of Arakoda in the U.S. market. Kodatef is the branded version of tafenoquine for malaria prevention approved by the TGA for use in Australia.
The Company made this request of the FDA due to robust demand for Arakoda in late 2024 and early 2025, and the potential for delays in
the completion of new lots of Arakoda currently being commercially validated by our key supplier, PCI. Although we anticipate that new
commercial Arakoda lots will enter the supply chain prior to the exhaustion of existing inventory, Kodatef will be available to cover
any shortage through a specialty pharmacy that already carries Arakoda, and has the capacity to ship to customers in all 50 states.

●We issued an aggregate of 385,200 shares of common stock during the quarter upon the exercise of 385,200
pre-funded warrants issued in September 2024, resulting in proceeds of $1,926.

1:5 Reverse Stock Split

On November 6, 2024, our Board of Directors (“Board”)
approved a reverse stock split of our common stock at a split ratio ranging between 1:3 and 1:5, as determined by the Board in its sole
discretion. On November 6, 2024, a majority of our stockholders approved the proposed reverse stock split. On February 10, 2025, the Board
approved a 1-for-5 reverse split ratio. On February 18, 2025, we filed a Certificate of Amendment to the Certificate of Incorporation,
as corrected, with the Secretary of State of the State of Delaware that provides for a 1-for-12 split. On February 24, 2025, we effectuated
a 1-for-5 reverse stock split of our common stock (the “1:5 Reverse Stock Split”). Beginning February 24, 2025, our common
stock traded on The Nasdaq Capital Market on a split adjusted basis.

As a result of the 1:5 Reverse Stock Split, proportional
adjustments were made to the number of shares of common stock issuable upon exercise or conversion of our equity awards, warrants, and
other equity instruments convertible into common stock, as well as the respective exercise prices, if applicable in accordance with the
terms of the instruments. No fractional shares of common stock were issued in connection with the 1